IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by MidWestOne Financial Group Inc.

MidWestOne Financial Group Inc. increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,805 shares of the medical research company's stock after acquiring an additional 2,019 shares during the quarter. MidWestOne Financial Group Inc.'s holdings in IQVIA were worth $1,337,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. Merit Financial Group LLC boosted its stake in IQVIA by 32.8% during the 4th quarter. Merit Financial Group LLC now owns 4,293 shares of the medical research company's stock valued at $844,000 after purchasing an additional 1,060 shares during the period. UMB Bank n.a. increased its position in IQVIA by 72.8% during the fourth quarter. UMB Bank n.a. now owns 401 shares of the medical research company's stock worth $79,000 after acquiring an additional 169 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in shares of IQVIA by 16.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,172 shares of the medical research company's stock valued at $230,000 after buying an additional 169 shares during the period. Finally, Harbor Investment Advisory LLC increased its position in shares of IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 0.8%

Shares of IQVIA stock traded down $1.08 during trading on Monday, hitting $136.96. The stock had a trading volume of 2,248,506 shares, compared to its average volume of 1,560,203. The stock has a market cap of $23.69 billion, a PE ratio of 18.26, a PEG ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The firm's fifty day simple moving average is $155.33 and its 200-day simple moving average is $183.13. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the business posted $2.54 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Barclays decreased their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Morgan Stanley boosted their price objective on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Finally, Truist Financial reduced their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.